Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 6, 2019
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how well three medications—cabozantinib, nivolumab, and ipilimumab—work together to treat patients with rare genitourinary tumors that have spread to other parts of the body. Cabozantinib is a targeted therapy that may help stop the growth of cancer cells, while nivolumab and ipilimumab are types of immunotherapy that help the body’s immune system fight cancer. The study aims to see if this combination is more effective than using any of these drugs alone for patients who have limited treatment options.
To participate in this trial, patients must be at least 18 years old and have specific types of metastatic genitourinary cancers, such as certain bladder or kidney cancers. They should have measurable disease confirmed by imaging tests and may have received up to two previous cancer treatments. Participants can expect to take the medications orally and will be monitored closely for side effects and treatment response. It's important to note that women who are pregnant or breastfeeding cannot participate, and there are strict eligibility criteria to ensure patient safety. If you think this trial might be right for you or a loved one, please discuss it with your healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
- • One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
- • One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort.
- * Histologically confirmed diagnosis of one of the following metastatic cohorts:
- • Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded
- • Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma
- • Squamous cell carcinoma of the bladder (Cohort C) - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma)
- • Plasmacytoid urothelial carcinoma (Cohort D) - Tumor should show predominantly \> or equal \~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well)
- • Any penile cancer (Cohort E)
- • Sarcomatoid renal cell carcinoma (Cohort F) - Tumor should be predominantly sarcomatoid \~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed
- • Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC
- • Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial
- • Sarcomatoid urothelial carcinoma (Cohort H) - Tumor should show predominantly \~ 50% sarcomatoid differentiation
- • Renal medullary carcinoma (Cohort I) - Per World Health Organization (WHO) definition, ideally confirmed with immunostains
- • Bone-only metastatic GU tumors (non-prostate) (Cohort J) - All genitourinary histologies, except prostate are eligible
- • Renal Collecting Duct Carcinoma (Cohort K) - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma)
- • Urethra carcinoma (Cohort L) - May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder
- • H\&E slides from diagnostic tumor tissue for retrospective central pathology review
- • Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible)
- • Age \>= 18 years
- • Patients must be able to swallow oral formulation of the tablets
- • Karnofsky performance status \>= 80%
- • Absolute neutrophil count (ANC) \>= 1,000/mcL
- • Platelet count \>= 75,000/mcL
- • Total bilirubin =\< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =\< 3.0 mg/dL
- • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN) (or =\< 5 x ULN for patients with liver metastases or Gilbert's disease)
- • Creatinine =\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \>= 40 mL/min/1.73 m\^2 (calculated using the Chronic Kidney Disease Epidemiology \[CKD-EPI\] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal
- • Hemoglobin \>= 9 g/dL (transfusion of packed red blood cells \[PRBCs\] allowed)
- • Serum albumin \>= 3.2 g/dL
- • Lipase and amylase =\< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis
- • Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed
- • No prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors with the exception of patients with "urothelial carcinoma" histology (cohorts D, H, J, L)
- • Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable
- • Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment
- • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil \[PTU\] or methimazole) including physiologic oral corticosteroids are eligible
- • Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible
- • Women of childbearing potential must have a negative pregnancy test =\< 7 days prior to registration
- • Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea \>= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason
- • Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents
- • The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment
- * The patient has received no radiation therapy:
- • To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
- • To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment
- • To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
- • To any other site(s) within 2 weeks before the first dose of study treatment
- • The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment
- • The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
- • The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate
- • The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment
- • The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =\< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae
- • The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility
- • No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=\< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted
- • No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors
- • Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- * The patient has not experienced any of the following:
- • Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment
- • Hemoptysis of \>= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment
- • Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
- • The patient has no tumor invading any major blood vessels
- • The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible
- * The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
- * Cardiovascular disorders including:
- • Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.
- • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic, or \> 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
- • The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 28 days before randomization. Note: if initial QTcF is found to be \> 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =\< 500 ms, the subject meets eligibility in this regard
- • Any history of congenital long QT syndrome
- * Any of the following within 6 months before registration of study treatment:
- • Unstable angina pectoris
- • Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)
- • Stroke (including transient ischemic attack \[TIA\], or other ischemic event)
- • Myocardial infarction
- • Cardiomyopathy
- * No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
- * Any of the following that have not resolved within 28 days before the first dose of study treatment:
- • Active peptic ulcer disease
- • Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome
- * None of the following within 2 years before the first dose of study treatment:
- • Abdominal fistula or genitourinary fistula
- • Gastrointestinal perforation
- • Bowel obstruction or gastric outlet obstruction
- • Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment
- • Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible
- * No other clinically significant disorders such as:
- • Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment
- • Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
- • History of organ or allogeneic stem cell transplant
- • Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone \[TSH\], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)
- * No history of major surgery as follows:
- • Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery
- • Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement
- • Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery
- • No history of severe hypersensitivity reaction to any monoclonal antibody
- • No evidence of active malignancy, requiring systemic treatment within 2 years of registration
- • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
- • No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. If HBV sAG is positive, subsequent ribonucleic acid (RNA) polymerase chain reaction (PCR) must be negative
- • No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Brooklyn, New York, United States
Charleston, South Carolina, United States
Bethesda, Maryland, United States
Buffalo, New York, United States
Saint Louis, Missouri, United States
Flint, Michigan, United States
Denver, Colorado, United States
Flint, Michigan, United States
Burnsville, Minnesota, United States
Edina, Minnesota, United States
Waconia, Minnesota, United States
Maywood, Illinois, United States
Peoria, Illinois, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Anchorage, Alaska, United States
Oklahoma City, Oklahoma, United States
Great Falls, Montana, United States
New York, New York, United States
Saint Paul, Minnesota, United States
Chanute, Kansas, United States
Dodge City, Kansas, United States
Newton, Kansas, United States
Wellington, Kansas, United States
Winfield, Kansas, United States
Jackson, Mississippi, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Delaware, Ohio, United States
Lancaster, Ohio, United States
Sheridan, Wyoming, United States
Chicago, Illinois, United States
Cincinnati, Ohio, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Oakland, California, United States
Mount Vernon, Illinois, United States
Salina, Kansas, United States
Chillicothe, Ohio, United States
Yakima, Washington, United States
Salina, Kansas, United States
Coon Rapids, Minnesota, United States
Renton, Washington, United States
Urbana, Illinois, United States
Wichita, Kansas, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Shakopee, Minnesota, United States
Willmar, Minnesota, United States
Council Bluffs, Iowa, United States
Dayton, Ohio, United States
Effingham, Illinois, United States
Independence, Kansas, United States
Lawrence, Kansas, United States
Saint Joseph, Missouri, United States
Greenville, Ohio, United States
Mount Vernon, Ohio, United States
Bethlehem, Pennsylvania, United States
Longmont, Colorado, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Springfield, Illinois, United States
Pittsburgh, Pennsylvania, United States
Minneapolis, Minnesota, United States
Rochester, New York, United States
Birmingham, Alabama, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Clovis, California, United States
Los Angeles, California, United States
Washington, District Of Columbia, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
Duluth, Minnesota, United States
Saint Louis, Missouri, United States
Kearney, Nebraska, United States
Omaha, Nebraska, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Chapel Hill, North Carolina, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Knoxville, Tennessee, United States
Nashville, Tennessee, United States
Jacksonville, Florida, United States
Los Angeles, California, United States
Aurora, Illinois, United States
Lexington, Kentucky, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Kettering, Ohio, United States
Tulsa, Oklahoma, United States
Allentown, Pennsylvania, United States
Centralia, Washington, United States
Federal Way, Washington, United States
Lakewood, Washington, United States
Cape Girardeau, Missouri, United States
Aventura, Florida, United States
Oakland, California, United States
Martinez, California, United States
Coos Bay, Oregon, United States
Pueblo, Colorado, United States
New Orleans, Louisiana, United States
Fridley, Minnesota, United States
Robbinsdale, Minnesota, United States
Saint Louis Park, Minnesota, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Lima, Ohio, United States
Portland, Oregon, United States
Omaha, Nebraska, United States
Omaha, Nebraska, United States
Milwaukee, Wisconsin, United States
Fort Lauderdale, Florida, United States
Dallas, Texas, United States
Orlando, Florida, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
Saint Louis, Missouri, United States
Las Vegas, Nevada, United States
Marshfield, Wisconsin, United States
Portland, Oregon, United States
Newark, Ohio, United States
Mcpherson, Kansas, United States
Reno, Nevada, United States
Miami Beach, Florida, United States
Decatur, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
El Dorado, Kansas, United States
Kingman, Kansas, United States
Parsons, Kansas, United States
Pratt, Kansas, United States
Wichita, Kansas, United States
Helena, Montana, United States
Missoula, Montana, United States
Galesburg, Illinois, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Jackson, Michigan, United States
Lansing, Michigan, United States
Warren, Michigan, United States
Brainerd, Minnesota, United States
Duluth, Minnesota, United States
Duluth, Minnesota, United States
Lincoln, Nebraska, United States
Papillion, Nebraska, United States
Anchorage, Alaska, United States
Omaha, Nebraska, United States
Cape Girardeau, Missouri, United States
Peru, Illinois, United States
Des Moines, Iowa, United States
Pontiac, Michigan, United States
Maplewood, Minnesota, United States
Maplewood, Minnesota, United States
Stillwater, Minnesota, United States
Great Falls, Montana, United States
Findlay, Ohio, United States
Toledo, Ohio, United States
Bremerton, Washington, United States
Burbank, California, United States
Greenbrae, California, United States
Atlanta, Georgia, United States
Alton, Illinois, United States
Galesburg, Illinois, United States
Richmond, Indiana, United States
Ames, Iowa, United States
Pittsburg, Kansas, United States
Topeka, Kansas, United States
Wichita, Kansas, United States
Port Huron, Michigan, United States
Saginaw, Michigan, United States
Woodbury, Minnesota, United States
Joplin, Missouri, United States
Kansas City, Missouri, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Billings, Montana, United States
Missoula, Montana, United States
Reno, Nevada, United States
Boardman, Ohio, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Toledo, Ohio, United States
Troy, Ohio, United States
Warren, Ohio, United States
Youngstown, Ohio, United States
East Stroudsburg, Pennsylvania, United States
Tacoma, Washington, United States
Vancouver, Washington, United States
Minocqua, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Rice Lake, Wisconsin, United States
Sheboygan, Wisconsin, United States
Waukesha, Wisconsin, United States
West Allis, Wisconsin, United States
Weston, Wisconsin, United States
Kettering, Ohio, United States
Emeryville, California, United States
Colorado Springs, Colorado, United States
Lakewood, Colorado, United States
Burlington, Massachusetts, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Marietta, Ohio, United States
Newark, Ohio, United States
Springfield, Ohio, United States
Westerville, Ohio, United States
Zanesville, Ohio, United States
Bellingham, Washington, United States
Seattle, Washington, United States
Seattle, Washington, United States
Livonia, Michigan, United States
Mansfield, Ohio, United States
Bremerton, Washington, United States
Kennewick, Washington, United States
Sedro Woolley, Washington, United States
Clackamas, Oregon, United States
Newberg, Oregon, United States
Oshkosh, Wisconsin, United States
Littleton, Colorado, United States
New Ulm, Minnesota, United States
Boise, Idaho, United States
Hendersonville, North Carolina, United States
Tucson, Arizona, United States
Las Vegas, Nevada, United States
Louisville, Kentucky, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Boise, Idaho, United States
Fargo, North Dakota, United States
Parker, Colorado, United States
Joplin, Missouri, United States
Lake Success, New York, United States
Walla Walla, Washington, United States
Grafton, Wisconsin, United States
Grand Island, Nebraska, United States
Fort Smith, Arkansas, United States
Post Falls, Idaho, United States
Bloomington, Illinois, United States
Pekin, Illinois, United States
Hays, Kansas, United States
Liberal, Kansas, United States
Fergus Falls, Minnesota, United States
Bolivar, Missouri, United States
Branson, Missouri, United States
Saint Louis, Missouri, United States
Lawton, Oklahoma, United States
Bend, Oregon, United States
Erie, Pennsylvania, United States
Franklin, Tennessee, United States
Poulsbo, Washington, United States
Burlington, Wisconsin, United States
Germantown, Wisconsin, United States
Green Bay, Wisconsin, United States
Kenosha, Wisconsin, United States
Marinette, Wisconsin, United States
Milwaukee, Wisconsin, United States
Racine, Wisconsin, United States
Summit, Wisconsin, United States
Two Rivers, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Los Angeles, California, United States
Hot Springs, Arkansas, United States
Arroyo Grande, California, United States
Olathe, Kansas, United States
Jefferson City, Missouri, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Oklahoma City, Oklahoma, United States
Erie, Pennsylvania, United States
Nashville, Tennessee, United States
Bryan, Texas, United States
Longview, Washington, United States
Dearborn, Michigan, United States
Tucson, Arizona, United States
Emeryville, California, United States
Atlanta, Georgia, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Twin Falls, Idaho, United States
Baton Rouge, Louisiana, United States
Lee's Summit, Missouri, United States
Rolla, Missouri, United States
Rolla, Missouri, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Portsmouth, Ohio, United States
Oregon City, Oregon, United States
Monroeville, Pennsylvania, United States
Natrona Heights, Pennsylvania, United States
Bellevue, Washington, United States
Burien, Washington, United States
Edmonds, Washington, United States
Everett, Washington, United States
Issaquah, Washington, United States
Lacey, Washington, United States
Eau Claire, Wisconsin, United States
New Richmond, Wisconsin, United States
Urbana, Illinois, United States
Springfield, Illinois, United States
Belpre, Ohio, United States
Columbus, Ohio, United States
Delaware, Ohio, United States
Brooklyn, New York, United States
Longmont, Colorado, United States
Las Vegas, Nevada, United States
Monroeville, Pennsylvania, United States
Springfield, Ohio, United States
Saint Peters, Missouri, United States
Greensburg, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Anchorage, Alaska, United States
Great Falls, Montana, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Emmett, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Sandpoint, Idaho, United States
Clive, Iowa, United States
West Des Moines, Iowa, United States
Garden City, Kansas, United States
Great Bend, Kansas, United States
Manhattan, Kansas, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Caro, Michigan, United States
Chelsea, Michigan, United States
Clarkston, Michigan, United States
Clarkston, Michigan, United States
East China Township, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Livonia, Michigan, United States
Macomb, Michigan, United States
Macomb, Michigan, United States
Marlette, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Rochester Hills, Michigan, United States
Saginaw, Michigan, United States
Sterling Heights, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
West Branch, Michigan, United States
Ypsilanti, Michigan, United States
Minneapolis, Minnesota, United States
Anaconda, Montana, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Centerville, Ohio, United States
Dublin, Ohio, United States
Grove City, Ohio, United States
Marion, Ohio, United States
West Chester, Ohio, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Cody, Wyoming, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Colorado Springs, Colorado, United States
Durango, Colorado, United States
Durango, Colorado, United States
Creston, Iowa, United States
Bardstown, Kentucky, United States
Corbin, Kentucky, United States
Lexington, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Shepherdsville, Kentucky, United States
Commack, New York, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Aberdeen, Washington, United States
Enumclaw, Washington, United States
Seattle, Washington, United States
Shelton, Washington, United States
Tacoma, Washington, United States
Yelm, Washington, United States
Carbondale, Illinois, United States
Carterville, Illinois, United States
Danville, Illinois, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
New Lenox, Illinois, United States
O'fallon, Illinois, United States
Swansea, Illinois, United States
Yorkville, Illinois, United States
Louisville, Kentucky, United States
Brighton, Michigan, United States
Brownstown, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Clinton Township, Michigan, United States
Novi, Michigan, United States
West Bloomfield, Michigan, United States
Ypsilanti, Michigan, United States
Maple Grove, Minnesota, United States
Wyoming, Minnesota, United States
Bonne Terre, Missouri, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sunset Hills, Missouri, United States
Centerville, Ohio, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Findlay, Ohio, United States
Findlay, Ohio, United States
Franklin, Ohio, United States
Greenville, Ohio, United States
Kettering, Ohio, United States
Troy, Ohio, United States
Clackamas, Oregon, United States
Seattle, Washington, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
Dublin, California, United States
Ames, Iowa, United States
Boone, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Basking Ridge, New Jersey, United States
Clovis, California, United States
Walnut Creek, California, United States
Monticello, Minnesota, United States
Creve Coeur, Missouri, United States
Saint Louis, Missouri, United States
Carson City, Nevada, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Reno, Nevada, United States
Eau Claire, Wisconsin, United States
London, Kentucky, United States
Wexford, Pennsylvania, United States
Milwaukee, Wisconsin, United States
Kenner, Louisiana, United States
Mukwonago, Wisconsin, United States
Waukesha, Wisconsin, United States
Winchester, Massachusetts, United States
Westwood, Kansas, United States
Ashland, Wisconsin, United States
Gahanna, Ohio, United States
Phoenix, Arizona, United States
Orland Park, Illinois, United States
Fairway, Kansas, United States
Jefferson Hills, Pennsylvania, United States
Phoenix, Arizona, United States
San Luis Obispo, California, United States
Santa Maria, California, United States
Tawas City, Michigan, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Perrysburg, Ohio, United States
Buffalo, New York, United States
Metairie, Louisiana, United States
Seattle, Washington, United States
Fort Worth, Texas, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Pahrump, Nevada, United States
Beavercreek, Ohio, United States
Stevens Point, Wisconsin, United States
Johns Creek, Georgia, United States
Arroyo Grande, California, United States
Baton Rouge, Louisiana, United States
Springfield, Massachusetts, United States
Aitkin, Minnesota, United States
Deer River, Minnesota, United States
Hibbing, Minnesota, United States
Sandstone, Minnesota, United States
Virginia, Minnesota, United States
Hazleton, Pennsylvania, United States
Ashland, Wisconsin, United States
Metairie, Louisiana, United States
Ballwin, Missouri, United States
Washington, Missouri, United States
Newport Beach, California, United States
Port Huron, Michigan, United States
Bellevue, Nebraska, United States
Omaha, Nebraska, United States
Redmond, Oregon, United States
Burr Ridge, Illinois, United States
Lake Forest, Illinois, United States
Detroit Lakes, Minnesota, United States
Fosston, Minnesota, United States
Park Rapids, Minnesota, United States
Jamestown, North Dakota, United States
Springfield, Ohio, United States
Kingman, Arizona, United States
Dixon, Illinois, United States
Washington, Illinois, United States
Farmington, Missouri, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Peabody, Massachusetts, United States
Burnsville, Minnesota, United States
Bozeman, Montana, United States
Shelby, Michigan, United States
Cambridge, Minnesota, United States
Princeton, Minnesota, United States
Omaha, Nebraska, United States
Omaha, Nebraska, United States
Monroeville, Pennsylvania, United States
N. Huntingdon, Pennsylvania, United States
Richardson, Texas, United States
Cudahy, Wisconsin, United States
Frederick, Maryland, United States
Melrose Park, Illinois, United States
Homer Glen, Illinois, United States
Missoula, Montana, United States
Nampa, Idaho, United States
Alton, Illinois, United States
Springfield, Illinois, United States
Grand Island, Nebraska, United States
Perrysburg, Ohio, United States
Toledo, Ohio, United States
San Juan, , Puerto Rico
Shiloh, Illinois, United States
Mineola, New York, United States
Kansas City, Missouri, United States
Des Moines, Iowa, United States
Kalispell, Montana, United States
Dallas, Texas, United States
Troy, Ohio, United States
Nampa, Idaho, United States
Alcoa, Tennessee, United States
Pontiac, Michigan, United States
Pittsburg, Kansas, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Danville, Illinois, United States
Boone, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Los Angeles, California, United States
Ames, Iowa, United States
Canton, Michigan, United States
Minocqua, Wisconsin, United States
Sunset Hills, Missouri, United States
Marysville, Ohio, United States
Clive, Iowa, United States
Lansing, Michigan, United States
Hays, Kansas, United States
Jefferson City, Missouri, United States
Pontiac, Michigan, United States
Silverdale, Washington, United States
Dayton, Ohio, United States
Sandpoint, Idaho, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Detroit, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Flint, Michigan, United States
Warren, Michigan, United States
East China Township, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Olathe, Kansas, United States
Grosse Pointe Woods, Michigan, United States
Rochester Hills, Michigan, United States
Mount Vernon, Illinois, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Denver, Colorado, United States
Rolla, Missouri, United States
Pittsburg, Kansas, United States
Littleton, Colorado, United States
Parker, Colorado, United States
Cape Girardeau, Missouri, United States
Winchester, Massachusetts, United States
Patients applied
Trial Officials
Andrea B Apolo
Principal Investigator
Alliance for Clinical Trials in Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials